OMERS ADMINISTRATION Corp Takes Position in Pro-Dex, Inc. (NASDAQ:PDEX)

OMERS ADMINISTRATION Corp purchased a new position in Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,700 shares of the medical instruments supplier's stock, valued at approximately $313,000. OMERS ADMINISTRATION Corp owned 0.21% of Pro-Dex as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Bank of New York Mellon Corp bought a new position in shares of Pro-Dex during the fourth quarter valued at $202,000. Trexquant Investment LP bought a new stake in shares of Pro-Dex during the 4th quarter worth approximately $252,000. Integrated Quantitative Investments LLC purchased a new position in shares of Pro-Dex in the 4th quarter valued at $254,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Pro-Dex in the 4th quarter worth $255,000. Finally, Millennium Management LLC acquired a new stake in Pro-Dex during the 4th quarter worth about $260,000. 15.28% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Pro-Dex from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th.

Pro-Dex Stock Performance

Shares of PDEX stock traded up $0.62 during mid-day trading on Friday, hitting $46.24. 32,196 shares of the stock were exchanged, compared to its average volume of 30,316. The stock's fifty day simple moving average is $53.03 and its two-hundred day simple moving average is $47.01. The stock has a market capitalization of $150.79 million, a price-to-earnings ratio of 23.01 and a beta of 0.37. Pro-Dex, Inc. has a 12-month low of $16.84 and a 12-month high of $70.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.51. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. The firm had revenue of $17.41 million during the quarter, compared to the consensus estimate of $17.70 million. On average, analysts forecast that Pro-Dex, Inc. will post 2 EPS for the current year.

Insider Activity

In other news, Director Raymond E. Cabillot sold 7,674 shares of the company's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $45.00, for a total transaction of $345,330.00. Following the completion of the transaction, the director now owns 310,978 shares of the company's stock, valued at approximately $13,994,010. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 21,383 shares of company stock worth $1,031,182 over the last ninety days. Corporate insiders own 47.50% of the company's stock.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.